Nuvalent (NUVL)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.58 (+0.62%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Nuvalent (NUVL)
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Key Insights

Critical company metrics and information
  • Share Price

    $94.31
  • Market Cap

    $6.70 Billion
  • Total Outstanding Shares

    65.62 Million Shares
  • Total Employees

    127
  • Dividend

    No dividend
  • IPO Date

    July 29, 2021
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.nuvalent.com

Historical Stock Splits

If you bought 1 share of NUVL before March 10, 2017, you'd have 0.00 shares today.
Execution DateSplit Amount
March 10, 20171-for-1200000 (Reverse Split)

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities, Continuing$-45.82 Million
Net Cash Flow From Financing Activities$550.27 Million
Net Cash Flow From Financing Activities, Continuing$550.27 Million
Net Cash Flow From Investing Activities$-212.91 Million
Net Cash Flow From Operating Activities$-45.82 Million
Net Cash Flow$291.54 Million
Net Cash Flow, Continuing$291.54 Million
Net Cash Flow From Investing Activities, Continuing$-212.91 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Nonoperating Income/Loss$-7.97 Million
Diluted Average Shares$65.68 Million
Basic Average Shares$65.68 Million
Preferred Stock Dividends And Other Adjustments$0.00
Revenues$8.70 Million
Net Income/Loss Attributable To Parent$-84.34 Million
Operating Income/Loss$-76.33 Million
Research and Development$60.55 Million
Provision For Loan, Lease, And Other Losses$0.00
Income/Loss From Continuing Operations Before Tax$-84.31 Million
Income/Loss From Continuing Operations After Tax$-84.34 Million
Interest Income/Expense Operating, Net$8.70 Million
Interest Income/Expense After Provision For Losses$8.70 Million
Net Income/Loss Available To Common Stockholders, Basic$-84.34 Million
Diluted Earnings Per Share$1.28
Other Operating Expenses$15.78 Million
Benefits Costs and Expenses$93.00 Million
Net Income/Loss$-84.34 Million
Costs And Expenses$93.00 Million
Basic Earnings Per Share$1.28
Income Tax Expense/Benefit$40000.00
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Operating Expenses$76.33 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Current Liabilities$51.13 Million
Equity$1.12 Billion
Noncurrent Liabilities$16.60 Million
Noncurrent Assets$9.18 Million
Liabilities And Equity$1.19 Billion
Equity Attributable To Noncontrolling Interest$0.00
Assets$1.19 Billion
Liabilities$67.73 Million
Equity Attributable To Parent$1.12 Billion
Accounts Payable$15.93 Million
Current Assets$1.18 Billion
Other Current Liabilities$28.37 Million
Wages$6.83 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.